WIRE — She also said that those reforms should include greater transparency and accountability for the upstream buying groups that control the acquisition of about 90 per cent of generic medicines in the US retail market; and action against practices that needlessly delay generic competition beyond legitimate patent and statutory exclusivity periods, at the expense of American families and taxpayers
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.